secwatch.observer — SEC 8-K summary
======================================

Issuer:     PRECIGEN, INC. (PGEN)
CIK:        0001356090
Form:       8-K
Filed at:   2025-11-13T23:59:59+00:00
Accession:  0000950103-25-014683
Event type: earnings
Sentiment:  positive
Materiality: 0.90
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud

Precigen Reports Q3 2025 Financial Results; PAPZIMEOS Full FDA Approval in August
--------------------------------------------------------------------------------

- PAPZIMEOS (zopapogene imadenovec-drba) received full FDA approval in August 2025 for adults with RRP.
- Over 100 patients registered in PAPZIMEOS Patient Hub; more than 100 million lives covered by private insurance.
- Submitted Marketing Authorization Application to EMA for zopapogene imadenovec in November 2025.
- Cash, cash equivalents, and investments totaled $123.6 million as of September 30, 2025.
- Entered credit facility providing up to $125 million non-dilutive financing; received first tranche of $100 million.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1356090/000095010325014683/0000950103-25-014683-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1356090/000095010325014683/dp237316_8k.htm
  HTML page:      https://secwatch.observer/filing/0000950103-25-014683

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer